Koyfin Home > Directory > Health Care > Apellis Pharmaceuticals Inc > Long-term Debt / Equity

Apellis Pharmaceuticals Inc Long-term Debt / Equity Chart (APLS)

Apellis Pharmaceuticals Inc annual/quarterly Long-term Debt / Equity from 2017 to 2018.
  • Apellis Pharmaceuticals Inc Long-term Debt / Equity for the quarter ending December 12, 2018 was $16m a -30.83% decrease of -5m year over year
  • Apellis Pharmaceuticals Inc Long-term Debt / Equity for the last 12 months ending December 12, 2018 was $16m a -30.83% decrease of -5m year over year
  • Apellis Pharmaceuticals Inc Annual Long-term Debt / Equity for 2018 was $16m a -12.39% decrease of -2m from 2017
  • Apellis Pharmaceuticals Inc Annual Long-term Debt / Equity for 2017 was $18m
Other Ratios Metrics:
  • Apellis Pharmaceuticals Inc Total Debt / Capital for the quarter ending September 09, 2018 was $12m a -24.67% decrease of -3m year over year
  • Apellis Pharmaceuticals Inc Other Liabilities for the quarter ending December 12, 2018 was $0m a -57.45% decrease of 0m year over year
  • Apellis Pharmaceuticals Inc Total Debt / Equity for the quarter ending September 09, 2018 was $14m a -29.04% decrease of -4m year over year
View Chart On Koyfin

Quarterly APLS Long-term Debt / Equity Data

12/2018$16m
09/2018$14m
06/2018$12m
03/2018$21m
12/2017$18m

Annual APLS Long-term Debt / Equity Data

2018$16m
2017$18m